EIR Ventures
  • This is Eir Ventures
  • Team
  • Investments
  • Sustainability
  • News
  • Contact
    • Investor Login
    • Download
Select Page
IO Biotech, Inc. Announces Pricing of Initial Public Offering

IO Biotech, Inc. Announces Pricing of Initial Public Offering

by Thomas Rønn | Nov 5, 2021 | Press Releases, Uncategorised

Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology. Read the...

Recent Posts

  • Eir Ventures Invests in Purpose Pharma
  • Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain
  • Eir Ventures invests in Dania Tx
  • Eir Ventures celebrates 3 years anniversary
  • Lovisa Backemar new Principal.

Recent Comments

    Supported by:

    Eir Ventures is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

    Supported by:

    Financing is made possible through financial backing of the Swedish government owned company Saminvest AB.

    Signatory of:

    ©2024 Eir Ventures.